HC Wainwright Predicts Weaker Earnings for Orchestra BioMed

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) – HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for Orchestra BioMed in a note issued to investors on Wednesday, August 12th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.41) per share for the quarter, down from their prior forecast of ($0.39). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Orchestra BioMed’s FY2026 earnings at ($1.52) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.42) EPS, Q3 2027 earnings at ($0.40) EPS and FY2027 earnings at ($1.63) EPS.

Several other equities research analysts have also commented on the stock. Barclays lifted their price target on shares of Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Wall Street Zen lowered Orchestra BioMed from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Piper Sandler reissued an “overweight” rating and issued a $10.00 target price (up from $9.00) on shares of Orchestra BioMed in a research report on Tuesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Orchestra BioMed in a report on Friday, July 17th. Finally, B. Riley Financial decreased their target price on shares of Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $13.00.

Orchestra BioMed Stock Performance

Shares of OBIO stock opened at $4.45 on Friday. Orchestra BioMed has a 12 month low of $2.20 and a 12 month high of $5.42. The company has a current ratio of 7.03, a quick ratio of 7.01 and a debt-to-equity ratio of 0.35. The company has a market cap of $267.44 million, a P/E ratio of -5.24 and a beta of 0.50. The firm has a fifty day moving average price of $4.01 and a 200 day moving average price of $4.11.

Orchestra BioMed (NASDAQ:OBIO) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.01. Orchestra BioMed had a negative net margin of 184.60% and a negative return on equity of 127.86%. The company had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.14 million.

Hedge Funds Weigh In On Orchestra BioMed

Large investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in shares of Orchestra BioMed during the 2nd quarter valued at $10,832,000. Alyeska Investment Group L.P. purchased a new stake in shares of Orchestra BioMed during the third quarter worth $3,386,000. Pathstone Holdings LLC acquired a new stake in Orchestra BioMed during the third quarter valued at $2,495,000. Rice Hall James & Associates LLC acquired a new stake in Orchestra BioMed during the second quarter valued at $1,830,000. Finally, Vanguard Group Inc. grew its stake in Orchestra BioMed by 28.0% in the third quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock valued at $3,675,000 after purchasing an additional 324,558 shares in the last quarter. Institutional investors and hedge funds own 53.20% of the company’s stock.

Insider Activity

In related news, insider Darren Sherman sold 15,000 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $4.09, for a total value of $61,350.00. Following the completion of the transaction, the insider owned 1,154,327 shares in the company, valued at $4,721,197.43. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.50% of the stock is owned by company insiders.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical?stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high?unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early? and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.